Trial Search Results

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

The main purpose of this study is to evaluate clinical efficacy and safety of bintrafusp alfa in participants with advanced, unresectable cervical cancer with disease progression during or after platinum-containing chemotherapy.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

EMD Serono Research & Development Institute, Inc.

Collaborator: Merck KGaA, Darmstadt, Germany

Stanford Investigator(s):


  • Drug: Bintrafusp alfa


Phase 2


Inclusion Criteria:

   - Participants have advanced unresectable and/or metastatic cervical cancer (squamous
   cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma) with disease progression
   during or after the prior platinum-containing chemotherapy:

      1. The prior platinum-containing chemotherapy may be a systemic treatment for
      advanced unresectable, recurrent, persistent or metastatic disease or treatment
      in the adjuvant or neo-adjuvant setting with disease progression or recurrence
      within 6 months of completion of platinum-containing chemotherapy

      2. Participants who previously only received platinum as a radiosensitizer are not

      3. Participants must be na├»ve to checkpoint inhibitors

   - Participants must have measurable disease

   - Participants must provide a tumor tissue sample, either from archival tissue or newly
   obtained core or excisional biopsy. If the participant received local therapy (For
   example: radiation therapy or chemoradiotherapy) after the archival tissue was taken,
   a new biopsy will be required

   - Participants who have Eastern Cooperative Oncology Group (ECOG) PS of 0 to 1

   - Life expectancy greater than or equals to (>=) 12 weeks as judged by the Investigator

   - Adequate hematological, hepatic and renal function as defined in the protocol

   - Participants with known Human Immunodeficiency Virus (HIV) infections are in general
   eligible if the following criteria are met:

      1. Clinically indicated participants must be stable on antiretroviral therapy (ART)
      for at least 4 weeks and agree to adhere to ART

      2. have no evidence of documented multi-drug resistance that would prevent effective

      3. Have an HIV viral load of < 400 copies per milliliter (/mL) at Screening

      4. Have CD4+ T-cell (CD4+) counts >= 350 cells/microliter

      5. For participants with a history of an Acquired immunodeficiency syndrome
      (AIDS)-defining opportunistic infection within the last 12 months, participants
      may be eligible only after consultation and agreement with the study Medical

      6. If prophylactic antimicrobial drugs are indicated, participants may still be
      considered eligible upon agreement with the study Medical Monitor

   - Participants with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections
   are in general eligible if the following criteria are met:

      1. HBV viral load below the limit of quantification. If medically indicated,
      participants infected with HBV must be treated and on a stable dose of antivirals
      at study entry and with planned monitoring and management according to
      appropriate labeling guidance

      2. Participants with a history of HCV infection should have completed curative
      antiviral treatment and require HCV viral load below the limit of quantification

      3. Participants on concurrent HCV treatment should have HCV below the limit of

   - Other protocol defined inclusion criteria could apply

Exclusion Criteria:

   - Participants with active central nervous system (CNS) metastases causing clinical
   symptoms or require therapeutic intervention are excluded. Participants with a history
   of treated CNS metastases (by surgery or radiation therapy) are not eligible unless
   they have fully recovered from treatment, demonstrated no progression for at least 4
   weeks, and are not using steroids for at least 7 days prior to the start of study

   - Participants with interstitial lung disease or has had a history of pneumonitis that
   has required oral or intravenous (IV) steroids

   - Participants with significant acute or chronic infections

   - Participants with active autoimmune disease that might deteriorate when receiving an
   immunostimulatory agent

   - Participants with clinically significant cardiovascular/cerebrovascular disease
   including: cerebral vascular accident/stroke, myocardial infarction, unstable angina,
   congestive heart failure, or serious cardiac arrhythmia

   - Other protocol defined exclusion criteria could apply

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Bela Shah
Not Recruiting